Malignant melanoma is increasing in incidence, and, though early lesio
ns are readily treatable, systemic therapy for metastatic disease rema
ins disappointing. Integrins are a family of cell-surface molecules th
at mediate adhesion between the cell and the extracellular matrix. One
member of the integrin family, the alpha v beta 3 integrin, is associ
ated with progression of melanomas, in that the most malignant cells e
xpress the highest levels of alpha v beta 3. Like many members of the
integrin family, alpha v beta 3 recognizes the sequence Arg-Gly-Asp (R
GD) in its ligands, and other molecules that contain this sequence wil
l compete with the natural ligands (such as vitronectin) for binding.
There is growing evidence that integrins function as receptors for sig
nal transduction, and that integrin-mediated signalling can affect cel
l behaviour and even cell survival. Under certain circumstances, loss
of integrin-mediated signalling will induce apoptosis, or programmed c
ell death, and we have demonstrated that melanoma cells treated with a
cyclic peptide with high affinity for the alpha v beta 3 integrin wil
l undergo apoptosis within three days. This mechanism might be exploit
ed therapeutically.